Barclays

Barclays’s Xilio Therapeutics XLO Stock Holding History

Barclays’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-89	Closed	-$8K	–	5299
2022 Q1	$8K	Buy	+89	New	+$14.1K	﹤0.01%	4641

Other funds holding XLO

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Barclays's XLO Position: Q2 2022 in Review

Barclays sold out of Xilio Therapeutics (XLO) in Q2 2022, closing a stake of 89 shares — an estimated $8K sold.

Barclays first reported a position in XLO in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2022.

Barclays reported no remaining Xilio Therapeutics position as of Q2 2022 after selling out during the quarter.
Barclays sold 89 Xilio Therapeutics shares in Q2 2022, an estimated $8K.
Barclays first reported a position in Xilio Therapeutics in Q1 2022 and held it in 1 quarter.
Barclays's Xilio Therapeutics position peaked at $8K in Q1 2022.
32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.